Immunogen (Immunogen) Float Percentage Of Total Shares Outstanding : 99.72% (As of May. 06, 2024)

View and export this data going back to 1989. Start your Free Trial

What is Immunogen Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Immunogen's float shares is 278.57 Mil. Immunogen's total shares outstanding is 279.35 Mil. Immunogen's float percentage of total shares outstanding is 99.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Immunogen's Insider Ownership is 0.90%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Immunogen's Institutional Ownership is 42.83%.

Immunogen Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Immunogen's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	278.57	/	279.35
	=	99.72%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunogen (Immunogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

IMGN:Mexico IMU:Germany

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.immunogen.com

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Executives

Theresa Wingrove	officer: VP of Regulatory Affairs	IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini	officer: V.P.-Fin., Prin. Acctg. Off.	830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen	officer: Chief Business Officer	11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White	officer: SVP, CFO and PFO	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy	director, officer: Chief Executive Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos	officer: SVP & CHIEF COMMERCIAL OFFICER	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles	officer: EVP R&D & MEDICAL AFFAIRS	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char	officer: SVP & CHIEF LEGAL OFFICER	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith	officer: SVP & Chief Commercial Officer	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain	director	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster	officer: V.P.-Fin., Prin. Acctg. Off.	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller	officer: SVP and CFO	45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows	officer: Vice-President,General Counsel	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451